Biocon is currently trading at Rs. 285.00, up by 0.80 points or 0.28% from its previous closing of Rs. 284.20 on the BSE.
The scrip opened at Rs. 283.50 and has touched a high and low of Rs. 286.00 and Rs. 279.35 respectively. So far 15964 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 341.43 on 25-Jan-2019 and a 52 week low of Rs. 211.30 on 20-Aug-2019.
Last one week high and low of the scrip stood at Rs. 304.00 and Rs. 275.05 respectively. The current market cap of the company is Rs. 34104.00 crore.
The promoters holding in the company stood at 60.67%, while Institutions and Non-Institutions held 20.76% and 18.58% respectively.
Biocon’s subsidiary-- Biocon Biologics India has received its board approval for primary equity investment by True North. As per the terms of the proposed agreement, True North will Invest Rs 536.25 crore in Biocon Biologics that will eventually translate to a 2.44% minority stake in the biosimilars business post all restructuring, including the filed merger of Biocon Research with Biocon Biologics, valuing Biocon Biologics at Rs 21,450 crore or $3 billion on a pre-money equity basis. Post the completion of this transaction, Biocon will hold 96.07% stake in Biocon Biologics.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1808.20 |
| Dr. Reddys Lab | 1322.95 |
| Cipla | 1309.90 |
| Zydus Lifesciences | 891.65 |
| Lupin | 2303.70 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: